Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Nov;24(5):713–715. doi: 10.1128/aac.24.5.713

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

P G Higgins, R J Phillpotts, G M Scott, J Wallace, L L Bernhardt, D A Tyrrell
PMCID: PMC185930  PMID: 6318655

Abstract

In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.

Full text

PDF
713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  2. Phillpotts R. J. Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirus. J Virol Methods. 1983 May;6(5):267–269. doi: 10.1016/0166-0934(83)90041-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Phillpotts R. J., Scott G. M., Higgins P. G., Wallace J., Tyrrell D. A., Gauci C. L. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2. Antiviral Res. 1983 Aug;3(2):121–136. doi: 10.1016/0166-3542(83)90034-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Phillpotts R. J., Wallace J., Tyrrell D. A., Freestone D. S., Shepherd W. M. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol. 1983;75(1-2):115–121. doi: 10.1007/BF01314131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  6. Scott G. M., Phillpotts R. J., Wallace J., Secher D. S., Cantell K., Tyrrell D. A. Purified interferon as protection against rhinovirus infection. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1822–1825. doi: 10.1136/bmj.284.6332.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES